Exchange: NASDAQ·Updated 05:55 AM EDT
ZYME logo

ZYMEZymeworks Inc

$25.85
$0.13
(0.51%)
Pre-Market
Prev Close $25.72
EarningsAug 6
Mkt Cap$1.92B
Vol4,524.00
News
all
press releases
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
Theravance Stock Down 3% After Zymeworks Announces Buyout
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zacks
News Placeholder
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.read more...
Benzinga
News Placeholder
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders
Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years.
Stocktwits
News Placeholder
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery PR Newswire VANCOUVER, BC, June 18, 2026 Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EMbased...
PR Newswire
News Placeholder
Zymeworks (ZYME) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -510.13% and -94.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of +2.86% and -48.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Pictet Asset Management Holding SA Invests $1.97 Million in Zymeworks Inc. $ZYME
Pictet Asset Management Holding SA purchased a new position in shares of Zymeworks Inc. (NASDAQ:ZYME - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing...
MarketBeat
News Placeholder
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates
Vertex (VRTX) delivered earnings and revenue surprises of +5.76% and +0.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.